Abiopharma

🔍 Adams Richard Welker III (Executive)

Company: Enhanced Group Inc. (ENHA)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 570,159 shares of Stock Option (Right to buy) at $1.23 per share (Derivative)
  Date: 2026-05-07 | Code: A | Expires: 2035-10-29 | equity_swap_involved: 0 | shares_owned_after: 570,159.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Acquired 45,141 shares of Award (Right to receive) (Derivative)
  Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 45,141.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5

Footnotes:

• F1: Consists of securities acquired in connection with the transactions consummated on May 7, 2026, pursuant to that certain Business Combination Agreement, dated November 26, 2025 (the "Business Combination Agreement"), by and among A Paradise Acquisition Corp. ("A Paradise"), A Paradise Merger Sub 1 Inc. ("Merger Sub"), and Enhanced Ltd. ("Enhanced"), pursuant to which (i) Merger Sub merged with and into Enhanced, the separate corporate existence of Merger Sub ceased and Enhanced was the surviving corporation and a wholly owned subsidiary of A Paradise, (ii) Enhanced merged with and into A Paradise, the separate corporate existence of Enhanced ceased and A Paradise was the surviving corporation, and (iii) A Paradise changed its name to "Enhanced Group Inc." (the "Issuer") (the "Business Combination").
• F2: The acquisition of the Stock Options for Class A common stock, par value $0.0001, of the Issuer ("Class A common stock"), is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") pursuant to Rule 16b-3 under the Exchange Act. This Form 4 only reports the acquisition of securities of the Reporting Person pursuant to the Business Combination Agreement and does not reflect the purchase of securities by the Reporting Person.
• F3: The options were originally granted on October 29, 2025 and vest monthly over a four-year period measured from August 12, 2024 (the "Vesting Start Date"), subject to a one-year cliff.
• F4: In connection with the closing of the Business Combination, each outstanding option to purchase Enhanced common shares, whether vested or unvested, was exchanged for a comparable option to purchase that number of shares of Class A common stock of the Issuer based on the exchange ratio as defined in the Business Combination Agreement (the "Exchange Ratio"). The exercise price for each such option was also accordingly adjusted based on the Exchange Ratio.
• F5: The award will be paid by the Issuer in 2026 in a lump sum of shares of Class A common stock. In connection with the closing of the Business Combination, each award to receive Enhanced common shares was exchanged for a comparable award to receive a number of shares of Class A common stock of the Issuer based on the Exchange Ratio.